11

12
Cheever Martin A, Gheysen Dirk: Her-2/neu fusion proteins. Corixa, Smithkline Beecham Biolog, July 23, 2003: EP1328631-A2

The present invention is generally directed to Her-2/neu fusion proteins, nucleic acid molecules encoding Her-2/neu fusion proteins, viral vectors expressing Her-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the Her-2/neu fusion proteins and/or nucleic acid molec ...


13
Hand Zimmermann Susan, Cheever Martin A, Foy Teresa M, Lodes Michael J, Kalos Michael D, Mcneill Patricia D, Vedvick Thomas S: Compositions and methods for the therapy and diagnosis of her-2/neu-associated malignancies. Corixa, December 3, 2003: EP1366153-A2

Compositions and methods for the therapy and diagnosis of cancer, particularly Her-2/neu-associated cancers, are disclosed. Illustrative compositions comprise one or more Her-2/neu polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that ...


14

15
Gaiger Alexander, Cheever Martin A: Methods for diagnosis and therapy of hematological and virus-associated malignancies. Corixa Corporation, Gaiger Alexander, Cheever Martin A, sPOTTER Jane E R, March 29, 2001: WO/2001/021192

The present invention is directed to methods for detecting and treating hematological and virus-associated malignancies using Her2/neu sequences. The Her2/neu sequences may be polypeptides or polynucleotides.


16
Cheever Martin A, Peace David J: Immune reactivity to expressed activated oncogenes for diagnosis and treatment of malignancy. Washington Research Foundation, sSHARKEY Richard G, August 8, 1991: WO/1991/011719

Methods for the detection, monitoring and treatment of malignancies are disclosed. Detection of the proliferation of T cells in response to $i(in vitro) exposure to a protein expression product of an acivated oncogene or cancer-related gene associated with a malignancy, or detection of immunocomplex ...


17
Cheever Martin A, Gaiger Alexander: Compositions and methods for diagnosis and therapy of malignant mesothelioma. Corixa Corporation, PARENT Annette S, August 30, 2001: WO/2001/062920

Disclosed are compositions and methods for the diagnosis and therapy of Wilms' tumor antigen-associated cancers, and in particular, mesotheliomas. In particular embodiments, the invention provides methods, compositions and kits for eliciting immune and T cell response to Wilms' tumor antigen polypep ...


18
Chen Wei, Cheever Martin A: Compositions and methods of using terminally labeled peptides that bind mhc class i molecules. University Of Washington, sNOTTENBURG Carol Ph D, December 19, 1996: WO/1996/041188

The present invention provides peptides that bind to MHC class I molecules. The peptide has a core of 7 to 14 amino acids linked at either its N- or C- terminus to at least two amino acids. The terminal-most additional amino acid contains a reporter group. Thepeptides may be used in a variety of met ...


19
Skeiky Yasir A W, Xu Jiangchun, Cheever Martin A, Reed Steven G: Compositions and methods for wt1 specific immunotherapy. Corixa Corporation, Skeiky Yasir A W, Xu Jiangchun, Cheever Martin A, Reed Steven G, sPOTTER Jane E R, April 12, 2001: WO/2001/025273

Compositions and methods for the therapy of malignant diseases, such as leukemia and cancer, are disclosed. The compositions comprise one or more of a WT1 polynucleotide, a WT1 polypeptide, an antigen-presenting cell presenting a WT1 polypeptide, an antibody that specifically binds to a WT1 polypept ...


20
Chen Wei, Cheever Martin A: Compositions and methods of using terminally labeled peptides that bind mhc class i molecules. Univ Washington, March 25, 1998: EP0830603-A1

The present invention provides peptides that bind to MHC class I molecules. The peptide has a core of 7 to 14 amino acids linked at either its N- or C- terminus to at least two amino acids. The terminal-most additional amino acid contains a reporter group. Thepeptides may be used in a variety of met ...